Similar articles for PMID: 26509518

Year	Number of Results
1990	1
1994	1
1996	2
1997	3
1998	3
1999	2
2001	2
2003	3
2004	3
2005	5
2006	3
2007	2
2008	8
2009	6
2010	11
2011	7
2012	5
2013	10
2014	12
2015	11
2016	12
2017	8
2018	3
2019	2
2020	3
2021	3
2022	3

1

Guidelines and Value-Based Decision Making: An Evolving Role for Payers.

McCauley JL. McCauley JL. N C Med J. 2015 Sep-Oct;76(4):243-6. doi: 10.18043/ncm.76.4.243. N C Med J. 2015. PMID: 26509518 Free article.

2

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.

McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. McGhan WF, et al. Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744291 Free article.

3

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J. Bekkering GE, et al. Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905

4

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Mauskopf JA, et al. Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x. Value Health. 2007. PMID: 17888098 Free article.

5

Cost-effectiveness and evidence evaluation as criteria for coverage policy.

Garber AM. Garber AM. Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-284-96. doi: 10.1377/hlthaff.w4.284. Health Aff (Millwood). 2004. PMID: 15451997

6

Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement.

Zannad F, Alonso Garcia MLA, Borer JS, Stough WG, Clutton-Brock T, Rosenberg Y, Packer M. Zannad F, et al. J Am Coll Cardiol. 2017 Dec 5;70(22):2822-2830. doi: 10.1016/j.jacc.2017.10.027. J Am Coll Cardiol. 2017. PMID: 29191332 Free article. Review.

7

What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.

Trosman JR, Weldon CB, Schink JC, Gradishar WJ, Benson AB 3rd. Trosman JR, et al. J Comp Eff Res. 2013 Jul;2(4):461-77. doi: 10.2217/cer.13.42. J Comp Eff Res. 2013. PMID: 24236686

8

Health technology assessment, value-based decision making, and innovation.

Henshall C, Schuller T; HTAi Policy Forum. Henshall C, et al. Int J Technol Assess Health Care. 2013 Oct;29(4):353-9. doi: 10.1017/S0266462313000378. Epub 2013 Jul 11. Int J Technol Assess Health Care. 2013. PMID: 23845404

9

Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?

Rizzo JD. Rizzo JD. Best Pract Res Clin Haematol. 2005;18(3):439-48. doi: 10.1016/j.beha.2005.01.021. Best Pract Res Clin Haematol. 2005. PMID: 15792918 Review.

10

Purchasing health insurance coverage for smoking cessation treatment: employers describe the most influential information in this decision.

Woolf NH, Burns ME, Bosworth TW, Fiore MC. Woolf NH, et al. Nicotine Tob Res. 2006 Dec;8(6):717-25. doi: 10.1080/14622200601004133. Nicotine Tob Res. 2006. PMID: 17132519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed